Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Respiratory Syncytial Virus Infections: full-pipeline trial registry
4 of 22 indexed Respiratory Syncytial Virus Infections trials are currently recruiting.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 4 currently recruiting · #756 of 28,707 conditions by registered trial count
Respiratory Syncytial Virus Infections: 22 US clinical trials tracked, 4 recruiting.
Respiratory Syncytial Virus Infections is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 11 of these trials.
Enrollment posture brief
Registry condition respiratory-syncytial-virus-infections
OPEN 4 | RECR 18% | LATE 9 | EARLY 12 | RANK #756 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of the Pancreas (18% recruiting · 11 trials)
Respiratory Syncytial Virus Infections lists 4 open slots (18% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Respiratory Syncytial Virus Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Respiratory Syncytial Virus Infections is recruiting below its size-band peers.
4 of 22 indexed trials (18.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Respiratory Syncytial Virus Infections research.
GlaxoSmithKline accounts for 11 of 22 trials (50%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Respiratory Syncytial Virus Infections enrolment sits around 300 participants.
Median target enrolment is 300 among the 22 trials that report a genuine target (sentinel values excluded). 5 of those (22.7%) plan for fewer than 100 participants.
-
Respiratory Syncytial Virus Infections research is mostly interventional.
21 interventional and 1 observational studies make up this index (95.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
University of Alabama at Birmingham
NCT05026749
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
Shionogi
NCT07214571
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
GlaxoSmithKline
NCT07092865
A Study of BLB-201 RSV Vaccine in Infants and Children
Blue Lake Biotechnology
NCT05655182
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
GlaxoSmithKline
NCT06534892
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
GlaxoSmithKline
NCT04732871
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
GlaxoSmithKline
NCT06573281
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
Codagenix
NCT04919109
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
GlaxoSmithKline
NCT05705440
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
GlaxoSmithKline
NCT05045144
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Regeneron Pharmaceuticals
NCT02325791
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
GlaxoSmithKline
NCT06374394
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
GlaxoSmithKline
NCT05059301
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
GlaxoSmithKline
NCT05966090
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
GlaxoSmithKline
NCT05921903
Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly
West Penn Allegheny Health System
NCT00609635
Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
Novavax
NCT01290419
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
GlaxoSmithKline
NCT02927873
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
Novavax
NCT02247726
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01852266
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02794870
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02040831
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Respiratory Syncytial Virus Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Respiratory Syncytial Virus Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Respiratory Syncytial Virus Infections page
22 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Respiratory Syncytial Virus Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Respiratory Syncytial Virus Infections trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Respiratory Syncytial Virus Infections condition card totals 22 registered trials; most-linked intervention RSVPreF3 OA investigational vaccine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.